Biomea Fusion IncBMEA
Price$1.30

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$45MTTM through 31 Mar 2026
Free Cash Flow -$62.2MTTM through 31 Mar 2026

Margins

Current

Returns

-240.2%ROE
-96.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio5.23x
Net Debt-$45.1Mnet cash position
Cash & Equivalents$45.1M

Quality Metrics

Earnings-Beat Rate100.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Metabolic Programs$0
View details

Advancing icovamenib in Phase II trials (COVALENT-211 and COVALENT-212) with topline data expected in Q4 2026, and BMF-650 in Phase I with initial weight loss data expected in Q2 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.